AWP
TEVA icon

Abacus Wealth Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Abacus Wealth Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-16,569
Closed -$499K – 496
2026
Q1 		$499K Buy
16,569
+559
+3% +$18K 0.05% 217
2025
Q4 		$500K Buy
+16,010
New +$394K 0.05% 221

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Abacus Wealth Partners's TEVA Position: Q2 2026 in Review

Abacus Wealth Partners sold out of Teva Pharmaceuticals (TEVA) in Q2 2026, closing a stake of 16,569 shares — an estimated $499K sold.

Abacus Wealth Partners first reported a position in TEVA in Q4 2025 and held it in 2 quarters. The position peaked at $500K in Q4 2025. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • Abacus Wealth Partners reported no remaining Teva Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Abacus Wealth Partners sold 16,569 Teva Pharmaceuticals shares in Q2 2026, an estimated $499K.
  • Abacus Wealth Partners first reported a position in Teva Pharmaceuticals in Q4 2025 and held it in 2 quarters.
  • Abacus Wealth Partners's Teva Pharmaceuticals position peaked at $500K in Q4 2025.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Abacus Wealth Partners's 13F filing for Q2 2026, filed 22 Jul 2026.